SpotOn Therapeutics
Eyeglasses for Alleviating Symptoms of Chronic Dizziness
Company Overview
Snapshot
Founded in February 2010, SpotOn Therapeutics operated with 1–10 employees. The company developed an innovative solution for chronic dizziness, but ceased operations in December 2019.
Business overview
SpotOn Therapeutics develops and offers a noninvasive treatment designed to alleviate symptoms of chronic dizziness, vertigo, and balance disorders. The company's core technology is implemented in an eyeglasses-like device called Neuro-Balance Active Spots (NBA Spots), which are embedded in specific locations on the lens and customized for each patient. These semitransparent NBA Spots do not affect normal vision and are fitted for distance vision, reading, or Plano, based on individual needs. The company operates in the Health Tech & Life Sciences sector, specifically within Digital Therapeutics, and serves patients suffering from chronic dizziness.
Log in to access full profile ›Company Intelligence Q&A
- What is SpotOn Therapeutics' primary product?
- SpotOn Therapeutics' primary product is SpotOn Specs, an eyeglasses-like device designed to alleviate symptoms of chronic dizziness, vertigo, and balance disorders using Neuro-Balance Active Spots (NBA Spots) embedded in the lenses.
- When was SpotOn Therapeutics founded?
- SpotOn Therapeutics was founded in February 2010.
- What is the operational status of SpotOn Therapeutics?
- SpotOn Therapeutics is currently non-active, having ceased operations in December 2019.
- What market does SpotOn Therapeutics primarily serve?
- SpotOn Therapeutics primarily serves the Israeli market, where its treatment was available.
- What is the core technology behind SpotOn Specs?
- The core technology behind SpotOn Specs involves Neuro-Balance Active Spots (NBA Spots), which are small, semitransparent rectangles embedded in the peripheral part of one or both lenses. These spots are personally fitted in terms of position, size, shape, and combination for each patient.